Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122782 | 1.00 | EPHX1 (0.50) | EPHX1CYP1A2TRPA1MEN1KMT2A | |
| SCHEMBL5561130 | 1.00 | EPHX1 (0.50) | EPHX1CYP1A2TRPA1MEN1KMT2A | |
| Acetic Acid SCHEMBL27580731 | 0.94 | ALPI (0.52) | EPHX1CYP1A2TRPA1MEN1KMT2A | |
| SCHEMBL7980662 | 0.80 | SLC7A5 (0.47) | CYP1A2MEN1KMT2ATAAR1SLC7A5 | |
| SCHEMBL17183114 | 0.80 | SLC7A5 (0.47) | CYP1A2MEN1KMT2ATAAR1SLC7A5 | |
| SCHEMBL16414796 | 0.78 | ACE (0.49) | CYP1A2TRPA1MEN1KMT2AKEAP1 | |
| SCHEMBL2322248 | 0.78 | ACE (0.49) | CYP1A2TRPA1MEN1KMT2AKEAP1 | |
| SCHEMBL27466706 | 0.78 | ACE (0.49) | CYP1A2TRPA1MEN1KMT2AKEAP1 | |
| SCHEMBL24320224 | 0.78 | MME (0.44) | — | |
| SCHEMBL12226226 | 0.78 | TRPA1 (0.46) | TRPA1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217480-A | 1,2,3, 4-tetrahydroisoquinoline compound and preparation method and application thereof | 南京工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | claimed |
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| JP-4401441-B2 | — | — | 2010-01-20 | — | — | JP | claimed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | claimed |
| EP-1511500-A4 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-04-29 | — | — | EP | claimed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | claimed |
| JP-2006504666-A | — | — | 2006-02-09 | — | — | JP | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| EP-1511500-A2 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | Epigenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| EP-0734715-A2 | 1,3-Butanediol thioglycolate isomer mixture and permanent waving composition comprising same | Kao Corporation (JP) | 1996-10-02 | — | — | EP | claimed |
| EP-0734716-A2 | Composition for permanent waving of human hair | Kao Corporation (JP) | 1996-10-02 | — | — | EP | claimed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | claimed |
| CN-1088912-A | The 4-amino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD (CH) | 1994-07-06 | — | — | CN | claimed |
| EP-0512270-A2 | Cosmetic composition | KAO CORPORATION (JP) | 1992-11-11 | — | — | EP | claimed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | claimed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | claimed |
| EP-0015036-B1 | PSYCHO-PHARMACOLOGICAL PEPTIDES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL COMPOSITIONS CONTAINING THEM | AKZO N.V. (NL) | 1983-05-04 | — | — | EP | claimed |
| US-4271152-A | FRAGMENTS OF B-LIPOTROPIN | AKZO N.V. (NL) | 1981-06-02 | — | — | US | claimed |
| EP-0015036-A1 | Psycho-pharmacological peptides, process for their preparation and therapeutical compositions containing them | AKZO N.V. (NL) | 1980-09-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | EPHX1 1965/4885CYP1A2 270/4885TRPA1 1847/4885 |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | EPHX1 3230/4885CYP1A2 749/4885TRPA1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.